日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer

更正：一项加拿大真实世界、多中心、前瞻性观察性研究，评估了接受内分泌治疗±靶向治疗的HR+HER2阴性晚期乳腺癌患者的治疗持续时间、治疗顺序和总生存期

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-026-07934-4
Doyle, Catherine; Lohmann, Ana Elisa; Iqbal, Nayyer; Henning, Jan-Willem; Kulkarni, Swati; Califaretti, Nadia; Hilton, John; Ferrario, Cristiano; Bouganim, Nathaniel; Mates, Mihaela; Guillemette, Stephanie; Leite, Ricardo; Caron, Marc-Andre; Thireau, Francois; Machado, Andres; Chia, Stephen
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Alloimmunization Due to Multiple Red Cell Antibodies in a RhD Positive Pregnancy: Lessons to be Learnt

RhD阳性妊娠中多种红细胞抗体引起的同种免疫：值得吸取的教训

期刊:
影响因子:
doi:10.1007/s12288-024-01952-2
Augustine, Merline; Parchure, Disha; Kshirsagar, Pooja; Bhembre, Shalaka; Mallya, M V; Adsule, Harshad; Sreekumar, Kavita; Kulkarni, Swati
细胞生物学
红细胞
免疫/内分泌
发表日期：2026
文献求助 收藏

Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis

三阴性乳腺癌肿瘤分级的临床意义：一项回顾性队列分析

期刊:Biomedicines
影响因子:3.9
doi:10.3390/biomedicines13051100
Ramanan, Neya; Malik, Mah-Noor; Upneja, Sarang; Farooq, Haniya; Kulkarni, Swati; Gupta, Rasna; Mathews, John; Nasser, Abdullah; Bocicariu, Alina; Arayan, Laurice; Porter, Lisa; Fifield, Bre-Anne; Luo, Rong; Brackstone, Muriel; Hamm, Caroline
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2- Advanced Breast Cancer

CDK4/6抑制剂在HR+/HER2-晚期乳腺癌一线姑息治疗中的真实世界经验

期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol32010052
Patel, Ram; Mathews, John; Hamm, Caroline; Kulkarni, Swati; Gupta, Rasna; Opperman, Tarquin; Chiong, John Dean; Nasser, Abdullah
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer

一项加拿大真实世界、多中心、前瞻性观察性研究，旨在评估接受内分泌治疗±靶向治疗的HR+HER2阴性晚期乳腺癌患者的治疗持续时间、治疗顺序和总生存期。

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-024-07580-8
Doyle, Catherine; Lohmann, Ana Elisa; Iqbal, Nayyer; Henning, Jan-Willem; Kulkarni, Swati; Califaretti, Nadia; Hilton, John; Ferrario, Cristiano; Bouganim, Nathaniel; Mates, Mihaela; Guillemette, Stephanie; Leite, Ricardo; Caron, Marc-Andre; Thireau, Francois; Machado, Andres; Chia, Stephen
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers

导管原位癌术前试验招募障碍：一项针对高危女性、幸存者和医护人员的探索性定性研究

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-025-07742-2
Adams, Elizabeth J; Zheng, Veronica; Cooper, Robin; Warwar, Samantha; Brown, Denisha; Schulte, Lauren; Kline, Danielle; Kulkarni, Swati A
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Identification of novel FUT1 gene mutation 346A>G in an Indian Bombay phenotype patient

在一名印度孟买表型患者中鉴定出新的FUT1基因突变346A>G

期刊:Transfusion
影响因子:2
doi:10.1111/trf.18321
Kulkarni, Swati; Navkudkar, Anisha; Merugu, Naga Muralidhar; Desai, Priti
发表日期：2025
文献求助 收藏

Unveiling Novel and Rare Variants in the α-1,4-Galactosyltransferase Gene Leading to Rare p Phenotype in Indian Patients

揭示α-1,4-半乳糖基转移酶基因中导致印度患者罕见p表型的新型和罕见变异

期刊:Transfusion Medicine and Hemotherapy
影响因子:1.9
doi:10.1159/000548316
Kshirsagar, Pooja; Raval, Goutham; Bhatnagar, Nidhi; Bonagiri, Shanthi; Noushad, Shahida; Madkaikar, Manisha; Kulkarni, Swati
发表日期：2025
文献求助 收藏

Pleomorphic Adenoma in the Setting of Triple-Negative Breast Cancer: A Case Report

三阴性乳腺癌合并多形性腺瘤：病例报告

期刊:Clinical Case Reports
影响因子:0.6
doi:10.1002/ccr3.70458
Guo, Michelle; Novo, Jorge; Schacht, David; Kulkarni, Swati
肿瘤免疫
肿瘤
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

一项针对新诊断的ER阳性、HER2阴性早期乳腺癌患者的术前机会窗口研究：口服选择性雌激素受体拮抗剂（SERD）伊姆伦司群的疗效：EMBER-2研究结果

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2113
Neven, Patrick; Stahl, Nicole; Vidal, Maria; Martín, Miguel; Kaufman, Peter A; Harbeck, Nadia; Hunt, Kelly K; Carter, Stacey; Bidard, Francois-Clement; Fasching, Peter A; Aftimos, Philippe; Wheatley, Duncan; Hamilton, Erika; Aft, Rebecca; Kulkarni, Swati; Schmid, Peter; Bhave, Manali; Ismail-Khan, Roohi; Karacsonyi, Claudia; Estrem, Shawn T; Nguyen, Bastien; Ozbek, Umut; Yuen, Eunice; Rodrik-Outmezguine, Vanessa; Ciruelos, Eva
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2024
文献求助 收藏